-
Jan 15, 2025 | 
mdpi.com | Myra Martel |Matthew Taylor |Shelley Kirychuk |Kwangseok Choi
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Nov 20, 2024 | 
jitc.bmj.com | Matthew Taylor |Aung Naing |John Powderly |Paul Woodard
MethodsThis is a first-in-human, multicenter, open-label, dose-escalation phase I trial (online supplemental file 1). The study evaluated the safety, PK, immunogenicity, clinical efficacy and biomarkers of intravenously administered IO-108 as monotherapy and in combination with pembrolizumab in patients with solid tumors that failed prior therapies.
-
Oct 11, 2024 | 
digitalcommons.library.tmc.edu | Vicky Makker |Matthew Taylor |Carol Aghajanian |Allen L. Cohn
BACKGROUND: Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 (NCT02501096). In these exploratory analyses from this study, we evaluated the associations between clinical outcomes and gene expression signature scores and descriptively summarized response in biomarker subpopulations defined by tumor mutational burden (TMB) and DNA variants for individual genes of interest.
-
Sep 10, 2024 | 
bmj.com | Harriet Haswell |Matthew Taylor
News & ViewsThe many costs of...
-
May 21, 2024 | 02345-5/abstract?rss=yes&sz=64)
europeanurology.com | Matthew Taylor |James J. Hsieh |Regina Gironés Sarrió |Christopher Di Simone |Chung-Han Lee |Amishi Yogesh Shah | +10 more
1 Taylor M.H. Lee C.H. Makker V. et al. Phase Ib/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 38: 1154-1163 ]. In the RCC cohort, LEN + PEM exhibited antitumor activity irrespective of prior treatment, and notably among patients who had received prior immune checkpoint inhibitors (ICIs) [ 2 Lee C.H. Shah A.Y. Rasco D. et al.
-
May 2, 2024 | 
biorxiv.org | Dina Dikovskaya |Rebecca Pemberton |Matthew Taylor |Anna Tasegian
AbstractMutations in Leucine-Rich Repeat protein Kinase 2 (LRRK2) are associated with Parkinson's Disease (PD) and Crohn's Disease (CD), but the regulation of LRRK2 during inflammation remains relatively unexplored. Here we developed a flow cytometry-based assay to assess LRRK2 activity in individual cells and created EGFP-LRRK2-knock-in reporter mouse to analyse cell-specific LRRK2 expression. Using these tools, we catalogued LRRK2 level and activity in splenic and intestinal tissues.
-
Apr 25, 2024 | 
biorxiv.org | Matthew Taylor |SYED AHMED |Ellena G Badenoch |David Bennett
AbstractTwo processes held in delicate balance during the fine tuning of synapse development are oxidative stress and autophagy: each can promote synapse expansion yet in excess are toxic. How this balance is maintained is not fully understood. While ataxia-telangiectasia mutated (ATM) is recognized as a key regulator of the DNA damage response, there is increasing evidence of a neuronal-specific role for this ubiquitous kinase and deficiency causes early-onset neurodegeneration.
-
Jan 10, 2024 | 
mdpi.com | Matthew Taylor |Shafiqur Rahman Tito |Martin Atkins |Mostafa Pasandideh
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Jan 1, 2024 | 
jitc.bmj.com | Vicky Makker |Matthew Taylor |Carol Aghajanian |Allen L. Cohn
Clinical/translational cancer immunotherapy Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146 Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.
-
Dec 16, 2023 | 
designspiration.com | Matthew Taylor
THE BEND on the Behance Network #bend #santos #the #letter #b #logo #henarejos #090909 #313131 #6e6e6e #bdbdbd #fbfbfb...
